- ISSN: 1871-5230
- E-ISSN: 1875-614X
-
s Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammatory Diseases
- Source: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, Volume 22, Issue 4, Dec 2023, p. 273 - 275
-
- 01 Dec 2023
Preview this article:
Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammatory Diseases, Page 1 of 1
< Previous page Next page > /docserver/preview/fulltext/aiaamc/22/4/s8-1.gif
There is no abstract available.
© Bentham Science Publishers
